Abstract
Pityriasis rubra pilaris (PRP) is an idiopathic, papulosquamous inflammatory dermatosis. It is characterized by hyperkeratotic follicular papules coalescing into orange-red scaly plaques, islands of sparing, and palmoplantar keratoderma. PRP can be subdivided into six clinical subtypes according to Griffiths’ classification, based on age of onset, disease extent, prognosis, and other associated features. The sixth subtype of PRP occurs in individuals affected by HIV infection, and retroviral screening in all de novo cases of PRP is advised. Other reported associations include various infections, autoimmunity, drugs, and malignancies, although the true significance of these is still unclear. The genetic basis for familial cases, most commonly categorized under the fifth subtype, has been mapped to gain of function mutations in the caspase recruitment domain family, member 14 (CARD14) gene. Treatment of PRP remains a challenge to this day due to a paucity of high-quality evidence. Therapeutic regimens have been guided mostly by case reports and case series, with the mainstay of treatment being oral retinoids. Recently, biologics have emerged as a promising treatment for PRP. We present a review of the clinicopathologic features, pathogenesis, associated disorders, and treatment of PRP, with an emphasis and critical appraisal of the existing literature on the latter.
This is a preview of subscription content, access via your institution.


References
Tarral C. General psoriasis. Desquamation from the parts covered with hair. Theor Pract Treatise Dis Skin. 1835;2:648–9.
Devergie MGA. Pityriasis pilaris, maladie de peau non decrite par les dermatologistes. Gaz Hebd Med Chir. 1856;3:197–201.
Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5:105–12.
Sehgal VN, Jain MK, Mathur RP. Pityriasis rubra pilaris in Indians. Br J Dermatol. 1989;121:821–2.
Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol. 1986;3:446–51.
Miralles ES, Núñez M, De Las Heras ME, Pérez B, Moreno R, Ledo A. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol. 1995;133:990–3.
Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol. 2010;11:157–70.
Conaghan PG, Sommer S, McGonagle D, Veale D, Waldmann H, Hale G, et al. The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. Arthritis Rheum. 1999;42:1998–2001.
Wood GS, Reizner GT. Other papulosquamous disorders. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. Philadelphia: Elsevier Ltd (Saunders); 2012.
González-López A, Velasco E, Pozo T, Del Villar A. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. Br J Dermatol. 1999;140:931–4.
Martin AG, Weaver CC, Cockerell CJ, Berger TG. Pityriasis rubra pilaris in the setting of HIV infection: clinical behaviour and association with explosive cystic acne. Br J Dermatol. 1992;126:617–20.
Blasdale C, Turner RJ, Leonard N, Ong ELC, Lawrence CM. Spontaneous clinical improvement in HIV-associated follicular syndrome. Clin Exp Dermatol. 2004;29:480–2.
Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91:163–70.
Vanderhooft SL, Francis JS, Holbrook KA, Dale BA, Fleckman P. Familial pityriasis rubra pilaris. Arch Dermatol. 1995;131:448–53.
Vasher M, Smithberger E, Lien MH, Fenske NA. Familial pityriasis rubra pilaris: report of a family and therapeutic response to etanercept. J Drugs Dermatol JDD. 2010;9:844–50.
Jordan CT, Cao L, Roberson EDO, Pierson KC, Yang C-F, Joyce CE, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90:784–95.
Takeichi T, Sugiura K, Nomura T, Sakamoto T, Ogawa Y, Oiso N, et al. Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations. JAMA Dermatol. 2017;153:66–70.
Eytan O, Qiaoli L, Nousbeck J, van Steensel MA, Burger B, Hohl D, et al. Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris. Br J Dermatol. 2014;170:1196–8.
Frazier CN, Ch’uan-K’uei H. Cutaneous lesions associated with a deficiency in vitamin A in man. Arch Intern Med. 1931;48:507–14.
Frazier CN, Ch’uan-K’uei H. Nature and distribution according to age of cutaneous manifestations of vitamin A deficiency: a study of two hundred and seven cases. Arch Dermatol Syphilol. 1936;33:825–52.
Loewenthal LJA. A new cutaneous manifestation in the syndrome of vitamin A deficiency. Arch Dermatol Syphilol. 1933;28:700–8.
Griffiths WA. Vitamin A and pityriasis rubra pilaris. J Am Acad Dermatol. 1982;7:555.
Gross DA, Landau JW, Newcomer VD. Pityriasis rubra pilaris: report of a case and analysis of the literature. Arch Dermatol. 1969;99:710–6.
Finzi AF, Altomare G, Bergamaschini L, Tucci A. Pityriasis rubra pilaris and retinol-binding protein. Br J Dermatol. 1981;104:253–6.
Van Voorst Vader PC, Van Oostveen F, Houthoff HJ, Marrink J. Pityriasis rubra pilaris, vitamin A and retinol-binding protein: a case study. Acta Derm Venereol. 1984;64:430–2.
Stoll DM, King LE, Chytil F. Serum levels of retinol binding protein in patients with pityriasis rubra pilaris. Br J Dermatol. 1983;108:375.
Vahlquist A. Retinol binding protein and pityriasis rubra pilaris [letter]. Br J Dermatol. 1982;107:125–6.
Magro CM, Crowson AN. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutan Pathol. 1997;24:416–24.
Yamamoto T, Yokoyama A. Lymphocyte response to superantigen in a patient with childhood-onset pityriasis rubra pilaris. Int J Dermatol. 1999;38:639–40.
Betlloch I, Ramón R, Silvestre JF, Carnero L, Albares MP, Bañuls J. Acute juvenile pityriasis rubra pilaris: a superantigen mediated disease? Pediatr Dermatol. 2001;18:411–4.
Kawara S, Miyake M, Oiso N, Kawada A. Pityriasis rubra pilaris with preceding cytomegalovirus infection. Dermatology. 2009;219:350–2.
Wang T, Liu J, Liu Y, Zheng H. Pityriasis rubra pilaris (PRP) with preceding Epstein-Barr virus infection: a new type PRP with non-HIV virus infection? Chin Med J (Engl). 2014;127:2391.
Erdem T, Atasoy M, Aliagaoglu C, Melikoglu M, Yildirim U. Pityriasis rubra pilaris in association with hepatitis A. Saudi Med J. 2006;27:1421–2.
Ertam I, Sezgin AO, Kazandi A, Dereli T, Unal I. A case of juvenile pityriasis rubra pilaris: could varicella be an aetiological agent? Clin Exp Dermatol. 2009;34:e1012–3.
Das JK, Gangopadhyay AK, Sengupta S. Pityriasis rubra pilaris with Koebner’s isomorphic phenomenon. Indian J Dermatol Venereol Leprol. 2010;76:194–6.
Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47:386–9.
Clayton BD, Jorizzo JL, Hitchcock MG, Fleischer AB, Williford PM, Feldman SR, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol. 1997;36:959–64.
Yang C-C, Shih I-H, Lin W-L, Yu Y-S, Chiu H-C, Huang P-H, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol. 2008;59:943–8.
Męcińska-Jundziłł K, Białecka A, Adamska U, Skrzeczko-Kwela E, Czajkowski R. Photosensitive pityriasis rubra pilaris. Postepy Dermatol Alergol. 2016;33:239–42.
Iredale HE, Meggitt SJ. Photosensitive pityriasis rubra pilaris. Clin Exp Dermatol. 2006;31:36–8.
Yaniv R, Barzilai A, Trau H. Pityriasis rubra pilaris exacerbated by ultraviolet B phototherapy. Dermatology. 1994;189:313.
Marguery MC, Durand-Malgouyres C, Bayle-Lebey P, Dupin P, Bazex J. Photosensitive and phototriggered pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed. 1994;10:42–5.
Evangelou G, Murdoch SR, Palamaras I, Rhodes LE. Photoaggravated pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed. 2005;21:272–4.
Kaskel P, Grundmann-Kollmann M, Schiller PI, Krähn G, Pillekamp H, Peter RU, et al. Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B. Br J Dermatol. 1999;140:769–70.
Jack A, Mauro MJ, Ehst BD. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib. J Am Acad Dermatol. 2013;69:e249–50.
Paz C, Querfeld C, Shea CR. Sorafenib-induced eruption resembling pityriasis rubra pilaris. J Am Acad Dermatol. 2011;65:452–3.
Plana A, Carrascosa JM, Vilavella M, Ferrandiz C. Pityriasis rubra pilaris-like reaction induced by imatinib. Clin Exp Dermatol. 2013;38:520–2.
Stalling SS, Vu JR, English JC. Telaprevir-induced pityriasis rubra pilaris-like drug eruption. Arch Dermatol. 2012;148:1215–7.
Cheung EJ, Jedrych JJ, English JC. Sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption. J Drugs Dermatol. 2015;14:1161–2.
Yang FC, Jessup C, Dahiya M, Reynolds R. Pityriasis rubra pilaris exacerbation with topical use of imiquimod. Int J Dermatol. 2008;47:1076–8.
Atanaskova MN, Dawes D, Sood A, Bergfeld W. Acantholytic pityriasis rubra pilaris. Case Rep Dermatol Med. 2011;2011:412684.
Gómez-Moyano E, Crespo-Erchiga A, Vera Casaño A, Sanz Trelles A. Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream [in Spanish]. Actas Dermosifiliogr. 2010;101:898–900.
López-Ferrer A, Dalmau J, Fernández-Figueras MT, Puig L. Pityriasis rubra pilaris triggered by photodynamic therapy with response to tumor necrosis factor α-blocking agents and acitretin. Cutis. 2014;93:E6–7.
Waldorf DS, Hambrick GW. Vitamin A—responsive pityriasis rubra pilaris with myasthenia gravis. Arch Dermatol. 1965;92:424–7.
Gül U, Gönül M, Kiliç A, Soylu S, Koçak O, Gönen B, et al. A case of pityriasis rubra pilaris associated with sacroileitis and autoimmune thyroiditis. J Eur Acad Dermatol Venereol. 2008;22:889–90.
Orlandini V, Cogrel O, Doutre MS, Beylot C, Beylot-Barry M. Pityriasis rubra pilaris and hypothyroidism. Efficacy of thyroid hormone replacement therapy in skin recovery. Br J Dermatol. 2007;156:606–7.
Franzotti AM, Avelar JCD, Cardoso TA, Pires MC, Vidigal Mdo R. Pityriasis Rubra Pilar and hypothyroidism. An Bras Dermatol. 2014;89:497–500.
Randle HW, Winkelmann RK. Pityriasis rubra pilaris and celiac sprue with malabsorption. Cutis. 1980;25:626–7.
Hazini AR, Rongioletti F, Rebora A. Pityriasis rubra pilaris and vitiligo in Down’s syndrome. Clin Exp Dermatol. 1988;13:334–5.
Bar-Ilan E, Gat A, Sprecher E, Zeeli T. Paraneoplastic pityriasis rubra pilaris: case report and literature review. Clin Exp Dermatol. 2017;42:54–7.
Sharma S, Weiss GR, Paulger B. Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma. Dermatology. 1997;194:166–7.
Batinac T, Kujundzić M, Peternel S, Cabrijan L, Troselj-Vukić B, Petranović D. Pityriasis rubra pilaris in association with laryngeal carcinoma. Clin Exp Dermatol. 2009;34:e917–9.
Kurzydlo A-M, Gillespie R. Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma. Australas J Dermatol. 2004;45:130–2.
Remedios IM, Jensen JD, Beckum K, McKay K, Kissel R. Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma. J Drugs Dermatol. 2014;13:610–2.
Garretson CB, Machan ML, Krejci-Manwaring J, Aires D, Tonkovic-Capin V. Adenocarcinoma of the lung associated with pityriasis rubra pilaris [letter]. Dermatol Online J. 2011;17:14.
Batchelor RJ, Yung A, Merchant W, Goodfield MJD. Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma? Clin Exp Dermatol. 2005;30:442–3.
Reinhardt LA, Rosen T. Pityriasis rubra pilaris as the initial manifestation of leukemia. Cutis. 1983;31:100–2.
Sánchez-Regaña M, López-Gil F, Salleras M, Umbert P. Pityriasis rubra pilaris as the initial manifestation of internal neoplasia. Clin Exp Dermatol. 1995;20:436–8.
Vitiello M, Miteva M, Romanelli P, Castaneda J, Garces-Milanes D, Kirsner R, et al. Pityriasis rubra pilaris: was it the first manifestation of colon cancer in a patient with pre-existing psoriasis? J Am Acad Dermatol. 2013;68:e43–4.
Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol. 1994;19:134–8.
Ingram J. Pityriasis rubra pilaris. Aust J Dermatol. 1960;5:177–84.
Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. Int J Dermatol. 2011;50:1480–5.
Rashidghamat E, Griffiths WAD, Mellerio JE, Robson A. Pityriasis rubra pilaris with histologic features of lichen nitidus. J Am Acad Dermatol. 2015;73:336–7.
Marrouche N, Kurban M, Kibbi A-G, Abbas O. Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon. Int J Dermatol. 2014;53:434–9.
Avitan-Hersh E, Bergman R. The incidence of acantholysis in pityriasis rubra pilaris-histopathological study using multiple-step sections and clinicopathologic correlations. Am J Dermatopathol. 2015;37:755–8.
Braun-Falco O, Ryckmanns F, Schmoeckel C, Landthaler M. Pityriasis rubra pilaris: a clinico-pathological and therapeutic study with special reference to histochemistry, autoradiography, and electron microscopy. Arch Dermatol Res. 1983;275:287–95.
Chan H, Liu FT, Naguwa S. A review of pityriasis rubra pilaris and rheumatologic associations. Clin Dev Immunol. 2004;11:57–60.
Marchetti MA, Greer KE. Pityriasis rubra pilaris treated with methotrexate resolving with an erythema gyratum repens-like appearance. J Am Acad Dermatol. 2013;69:e32–3.
Almaani N, Robson A, Sarkany R, Griffiths WAD. Erythema gyratum repens associated with pityriasis rubra pilaris. Clin Exp Dermatol. 2011;36:161–4.
Gebauer K, Singh G. Resolving pityriasis rubra pilaris resembling erythema gyratum repens. Arch Dermatol. 1993;129:917–8.
Caldarola G, Zampetti A, De Simone C, Massi G, Amerio P, Feliciani C. Circumscribed pityriasis rubra pilaris type IV. Clin Exp Dermatol. 2007;32:471–2.
Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol. 1999;38:1–11.
Lin W-L, Lin W-C, Shih I-H, Yang L-C, Hong H-S. Juvenile pityriasis rubra pilaris in Chang Gung Memorial Hospital, Taipei and Linkou: a retrospective study in the past ten years. Dermatol Sin. 2007;25:248–55.
Karimian-Teherani D, Parissa M, Tanew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Pediatr Dermatol. 2008;25:125–6.
Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol. 1994;130:675–8.
Jaimovich L, Mordoh A, Schroh R. Treatment of circumscribed juvenile type of pityriasis rubra pilaris with calcipotriol. J Dermatol Treat. 1997;8:211–2.
Gregoriou S, Argyriou G, Christofidou E, Vranou A, Rigopoulos D. Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%. J Drugs Dermatol. 2007;6:340–2.
Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6:710–5.
Borok M, Lowe NJ. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol. 1990;22:792–5.
Sanchez-Regana M, Creus L, Umbert P. Pityriasis rubra pilaris. A long-term study of 25 cases. Eur J Dermatol. 1994;4:593–7.
Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31:997–9.
Gemmeke A, Schönlebe J, Koch A, Wollina U. Pityriasis rubra pilaris–a retrospective single center analysis over eight years [in English, German]. J Dtsch Dermatol Ges. 2010;8:439–44.
Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014;150:92–4.
Lee HS, Lee E-S. Classic juvenile pityriasis rubra pilaris treated with oral alitretinoin. Ann Dermatol. 2016;28:388–90.
Yun CH, Kim JS, Ryu HR, Kim JH, Baek JO, Lee JR, et al. Circumscribed juvenile pityriasis rubra pilaris responsive to alitretinoin. Dermatol Ther. 2016;29:81–3.
PampÃn A, Gómez-de la Fuente E, Caro Gutiérrez MD, López-Estebaranz JL. Successful treatment of atypical adult pityriasis rubra pilaris with oral alitretinoin. J Am Acad Dermatol. 2013;69:e105–6.
Schmitt L, Inhoff O, Dippel E. Oral alitretinoin for the treatment of recalcitrant pityriasis rubra pilaris. Case Rep Dermatol. 2011;3:85–8.
Molin S, Ruzicka T. Treatment of refractory pityriasis rubra pilaris with oral alitretinoin: case report. Br J Dermatol. 2010;163:221–3.
Amann PM, Susic M, Glüder F, Berger H, Krapf W, Löffler H. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol. 2015;95:329–31.
Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003;49:171–82 (quiz 183–186).
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1–37.
Ormerod AD, Campalani E, Goodfield MJ, BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162:952–63.
Chapalain V, Beylot-Barry M, Doutre MS, Beylot C. Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. J Dermatol Treat. 1999;10:113–7.
van Dooren-Greebe RJ, van de Kerkhof PC. Extensive extraspinal hyperostoses after long-term oral retinoid treatment in a patient with pityriasis rubra pilaris. J Am Acad Dermatol. 1995;32:322–5.
Beck HI, Foged EK. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica. 1983;167:94–6.
Zachariae H. Dangers of methotrexate/etretinate combination therapy [letter]. Lancet. 1988;1:422.
Lim JT, Tham SN. Pityriasis rubra pilaris in Singapore. Clin Exp Dermatol. 1991;16:181–4.
Khoo L, Asawanonda P, Grevelink SA, Taylor CR. Narrow-band UVB-associated lesional blisters in pityriasis rubra pilaris. J Am Acad Dermatol. 1999;41:803–4.
Betto P, Vassilopoulou A, Colombari R, Veller-Fornasa C. Acute juvenile pityriasis rubra pilaris: a case report after mononucleosis infection. G Ital Dermatol Venereol. 2008;143:271–3.
Massa AF, Vasconcelos P, Soares de Almeida L, Filipe P. Pityriasis rubra pilaris mixed type III/IV successfully treated with narrow band-ultraviolet B. Indian J Dermatol Venereol Leprol. 2015;81:435.
Herbst RA, Vogelbruch M, Ehnis A, Kiehl P, Kapp A, Weiss J. Combined ultraviolet al radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol. 2000;142:574–5.
Neess CM, Hinrichs R, Dissemond J, Herrmann G, Poswig A, Servera-Llanras M, et al. Treatment of pruritus by capsaicin in a patient with pityriasis rubra pilaris receiving RE-PUVA therapy. Clin Exp Dermatol. 2000;25:209–11.
Kirby B, Watson R. Pityriasis rubra pilaris treated with acitretin and narrow-band ultraviolet B (Re-TL-01). Br J Dermatol. 2000;142:376–7.
Booth AV, Ma L. Pityriasis rubra pilaris, type 1. Dermatol Online J. 2005;11:9.
Vergilis-Kalner IJ, Mann DJ, Wasserman J, Petronic-Rosic V, Tsoukas MM. Pityriasis rubra pilaris sensitive to narrow band-ultraviolet B light therapy. J Drugs Dermatol. 2009;8:270–3.
Cox V, Lesesky EB, Garcia BD, O’Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol. 2008;59:S113–4.
Walling HW, Swick BL. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol. 2009;145:99–101.
Ivanova K, Itin P, Haeusermann P. Pityriasis rubra pilaris: treatment with biologics—a new promising therapy? Dermatology. 2012;224:120–5.
Adnot-Desanlis L, Antonicelli F, Tabary T, Bernard P, Reguiaï Z. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition. Dermatology. 2013;226:41–6.
Ruiz Villaverde R, Sánchez Cano D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol. 2010;20:630–1.
Müller H, Gattringer C, Zelger B, Höpfl R, Eisendle K. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol. 2008;59:S65–70.
Petrof G, Almaani N, Archer CB, Griffiths WA, Smith CH. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. J Eur Acad Dermatol Venereol. 2013;27:e131–5.
Karadag AS, Kavala M, Ozlu E, Ozkanlı S, Zindancı İ, Turkoglu Z. Erythrodermic pityriasis rubra pilaris: dramatic response to infliximab therapy. Indian J Dermatol Venereol Leprol. 2016;82:112.
Mattox AR, Chappell JA, Hurley MY. New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris. J Drugs Dermatol. 2013;12:217–9.
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg. 2003;7:382–6.
Barth D, Harth W, Treudler R, Simon JC. Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges. 2009;7:1071–4.
Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol. 2005;141:423–5.
Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol. 2006;47:124–9.
Ruiz-Genao DP, Lopez-Estebaranz JL, Naz-Villalba E, Gamo-Villegas R, Calzado-Villarreal L, Pinedo-Moraleda F. Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol. 2007;87:552–3.
Zirbs M, Kigitsidou E, Seifert F, Ring J, Brockow K. Successful treatment with infliximab despite positive tuberculosis ELISpot results in a patient with pityriasis rubra pilaris taking prophylactic isoniazid. Clin Exp Dermatol. 2011;36:808–9.
Dessinioti C, Vergou T, Moustou E, Katsambas A, Antoniou C. Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris. Eur J Dermatol. 2011;21:599–600.
Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010;24:881–4.
Ruzzetti M, Saraceno R, Carboni I, Papoutsaki M, Chimenti S. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. J Eur Acad Dermatol Venereol. 2008;22:117–8.
Vujic I, Richter L, Bartsch K, Monshi B, Rappersberger K. Pityriasis rubra pilaris types 1 and 2: different responses to treatment with TNF-alpha antagonists. Eur J Dermatol. 2013;23:895–6.
Lu R, George SJ, Hsu S. Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab. Dermatol Online J. 2006;12:18.
Salman A, Sonmez Y, Sahin H, Unal AU, Direskeneli H, Cinel L, et al. Infliximab-induced cutaneous eruption resembling pityriasis rubra pilaris in a patient with Takayasu’s arteritis. Dermatol Ther. 2017;30:e12443.
Kim JH, Park M-C, Kim S-C. Etanercept-induced clinical remission of type II pityriasis rubra pilaris with rheumatoid arthritis. Acta Derm Venereol. 2012;92:399–400.
Guedes R, Leite L. Therapeutic hotline. Treatment of pityriasis rubra pilaris with etanercept. Dermatol Ther. 2011;24:285–6.
Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol. 2008;158:642–4.
Davis KF, Wu JJ, Murase JE, Rosenberg FR, Sorenson EP, Meshkinpour A. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol. 2007;143:1597–9.
Gómez M, Ruelas MEH, Welsh O, Arcaute HD, Ocampo-Candiani J. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. J Drugs Dermatol. 2007;6:337–9.
Zhang Y-H, Zhou Y, Ball N, Su M-W, Xu J-H, Zheng Z-Z. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg. 2010;14:185–8.
Schreml S, Zeller V, Babilas P, Karrer S, Landthaler M, Szeimies R-M. Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol. 2010;35:792–3.
O’Kane D, Devereux CE, Walsh MY, Hoey SEH. Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment. Clin Exp Dermatol. 2010;35:e155–6.
Chiu H-Y, Tsai T-F. Pityriasis rubra pilaris with polyarthritis treated with adalimumab. J Am Acad Dermatol. 2013;68:187–8.
Wassef C, Lombardi A, Rao BK. Adalimumab for the treatment of pityriasis rubra pilaris: a case report. Cutis. 2012;90:244–7.
Bravo EA, Carrion L, Paucar SM, Mendoza R, Rivera C. Successful treatment of pityriasis rubra pilaris with adalimumab—case report. Dermatol Online J. 2014;20:22374.
Kim BR, Chae JB, Park JT, Byun SY, Youn SW. Clinical remission of pityriasis rubra pilaris with adalimumab in an adolescent patient. J Dermatol. 2015;42:1122–3.
Kitayama N, Nakamizo S, Kaku Y, Endo Y, Fujisawa A, Otsuka A, et al. Case of pityriasis rubra pilaris with annular pattern as an early manifestation. J Dermatol. 2017;44:478–9.
Park S-H, Cho G, Park S-G. NF-κB activation in T helper 17 cell differentiation. Immune Netw. 2014;14:14–20.
Feldmeyer L, Mylonas A, Demaria O, Mennella A, Yawalkar N, Laffitte E, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153:304–8.
Lernia VD, Ficarelli E, Zanelli M. Ineffectiveness of tumor necrosis factor-α blockers and ustekinumab in a case of type IV pityriasis rubra pilaris. Indian Dermatol Online J. 2015;6:207–9.
Lwin SM, Hsu C-K, Liu L, Huang H-Y, Levell NJ, McGrath JA. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14. Br J Dermatol. 2017. https://doi.org/10.1111/bjd.15462 (Epub 2017 Mar 16).
Eytan O, Sarig O, Sprecher E, van Steensel MA. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol. 2014;171:420–2.
Paganelli A, Ciardo S, Odorici G, Pellacani G, Conti A. Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT). J Eur Acad Dermatol Venereol. 2017;31:e249–51.
Byekova Y, Sami N. Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy. J Dermatol. 2015;42:830–1.
Chowdhary M, Davila U, Cohen DJ. Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris. Case Rep Dermatol. 2015;7:46–50.
Di Stefani A, Galluzzo M, Talamonti M, Chiricozzi A, Costanzo A, Chimenti S. Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. J Dermatol Case Rep. 2013;7:5–9.
Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol. 2010;163:655–6.
Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–63.
Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful treatment of refractory pityriasis rubra pilaris with secukinumab. JAMA Dermatol. 2016;152:1278–80.
Gauci M-L, Jachiet M, Gottlieb J, Madeleine-Chambrin I, Rybojad M, Bagot M, et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep. 2016;2:462–4.
Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972;87:42–5.
Anand CL, Rathore SB. Therapeutic efficacy of azathioprine in pityriasis rubra pilaris. Indian J Dermatol Venereol Leprol. 1984;50:54.
Usuki K, Sekiyama M, Shimada T, Shimada S, Kanzaki T. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology. 2000;200:324–7.
Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol. 2003;149:202–3.
Krase IZ, Cavanaugh K, Curiel-Lewandrowski C. Treatment of refractory pityriasis rubra pilaris with novel phosphodiesterase 4 (PDE4) inhibitor apremilast. JAMA Dermatol. 2016;152:348–50.
Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol. 2007;156:1055–6.
Popova L, Darlenski R, Tsankov N. Penicillin and vitamin A as possible therapeutic agents in pityriasis rubra pilaris. J Dtsch Dermatol Ges. 2010;8:354–6.
Ahn S-Y, Kim J-H, Ahn SK, Oh YS. Clinical improvement of pityriasis rubra pilaris with antibiotic therapy. Eur J Dermatol. 2011;21:106–7.
Coras B, Vogt TH, Ulrich H, Landthaler M, Hohenleutner U. Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris? Br J Dermatol. 2005;152:388–9.
Haenssle HA, Bertsch HP, Emmert S, Wolf C, Zutt M. Extracorporeal photochemotherapy for the treatment of exanthematic pityriasis rubra pilaris. Clin Exp Dermatol. 2004;29:244–6.
Hofer A, Müllegger R, Kerl H, Wolf P. Extracorporeal photochemotherapy for the treatment of erythrodermic pityriasis rubra pilaris. Arch Dermatol. 1999;135:475–6.
Auffret N, Quint L, Domart P, Dubertret L, Lecam JY, Binet O. Pityriasis rubra pilaris in a patient with human immunodeficiency virus infection. J Am Acad Dermatol. 1992;27:260–1.
Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol. 1991;24:703–5.
Bonomo RA, Korman N, Nagashima-Whalen L, Briggs J, Graham R, Salata RA. Pityriasis rubra pilaris: an unusual cutaneous complication of AIDS. Am J Med Sci. 1997;314:118–21.
De D, Dogra S, Narang T, Radotra BD, Kanwar AJ. Pityriasis rubra pilaris in a HIV-positive patient (Type 6 PRP). Skinmed. 2008;7:47–50.
Lerebours-Nadal L, Beck-Sague CM, Parker D, Gosman A, Saavedra A, Engel K, et al. Severe, disfiguring, pityriasis rubra pilaris in a woman in the Dominican Republic: histopathologic diagnosis and response to antiretroviral therapy. J Int Assoc Provid AIDS Care. 2016;15:11–4.
Perrin C, Durant JM, Lacour JP, Michiels JF, Dellamonica P, Ortonne JP. Horny perifollicular mucinosis. An atypical pityriasis rubra pilaris-like eruption associated with HIV infection. Am J Dermatopathol. 1993;15:358–62.
Resnick SD, Murrell DF, Woosley JT. Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: an HIV-associated follicular syndrome? J Am Acad Dermatol. 1993;29:283.
Menni S, Brancaleone W, Grimalt R. Pityriasis rubra pilaris in a child seropositive for the human immunodeficiency virus. J Am Acad Dermatol. 1992;27:1009.
OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford: Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 15 Dec 2017.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding support has been received for this study.
Conflict of interest
Dr. Hazel H. Oon is a clinical investigator for Janssen, Novartis, and Pfizer, and an advisory board member for AbbVie. Dr. Oon has also served as a speaker, advisory board member, and researcher for Galderma. Drs. V. C. L. Chong, D. Y. Wang, and W.S. Chong do not have any conflicts of interest to declare.
Rights and permissions
About this article
Cite this article
Wang, D., Chong, V.CL., Chong, WS. et al. A Review on Pityriasis Rubra Pilaris. Am J Clin Dermatol 19, 377–390 (2018). https://doi.org/10.1007/s40257-017-0338-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-017-0338-1